We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Customvis | CUS | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 0.93 | 01:00:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 0.93 | 0.93 |
| Top Posts |
|---|
Posted at 19/4/2010 11:49 by moosh2 it's just one company of hundreds/thousands that are out there. as long as you didn't squander everything into it, any losses can be made back easily enough! move on quickly and do NOT dwell!!and rather than thinking about it as a 'loss', think of it as more of you having given a charitable donation to someone whose dreams you believed in, and while you might have got some return on that, at least you were giving enough to believe in someone's efforts in the first place...and for all the science behind CUS (which appeared to be working), something just didn't work out. ok....so it doesn't help that much, but it puts a nicer glow on things :) |
Posted at 16/3/2010 10:22 by maytrees That trade at 1.12p was a buy - I SIPPed a few more CUS. |
Posted at 16/2/2010 20:10 by moosh2 i've made it my mission from yesterday to shove any gains i make on other shares into CUS once it goes intraday o/sold and/or MMs treeshake the chuffer to set me up a nice big free holding (by the time it gets to 2p+ lol!). let's hope there are no issues at moorfields trials!! when other companies release poor trial results, the share price kind of vanishes :o/ |
Posted at 30/12/2009 08:37 by eternaloptimist Look reasonably positive final results to me and I will focus on the"Although the past 12 months have been an extremely difficult period, we believe that much better times are not far away." and the * Revenue increased by 82% to GBP2.12m (2008: GBP1.16m) * Gross profit increased by 70% to GBP1.07m (2008: GBP0.63m) * Loss before tax (before unrealised gain on foreign exchange) reduced by almost 40% to GBP1.1m (2008: GBP1.82m) Hints of possible fund raising but at least seemingly not currently a pressurised one "By doing so the Directors are confident that they will be able to fund ongoing operations and growth by these and other options the Board is currently pursuing. One option may be to raise additional working capital at some stage in 2010." There may be hope for my few CUS shares - and added a few more this morning. |
Posted at 12/12/2009 19:07 by 1stclass CUS New thread - New beginning (CUS) ok stale mate - Good luck hope you lot get to get back in that were told to get out.... funny how craig was snapping em up while the bashers were selling :) no honestly stale mate :) bye |
Posted at 23/11/2009 10:34 by jaylett Yes, it is a decent update. As I said previously, hard sales of product and cash in the door is what is needed. I wonder if this positive RNS is timed to come out just before the annuals which are due very soon? I would expect them to be less than great given the expected sales for the previous year, however if CUS can demonstrate they are ramping up sales to market (as the last two RNS have done) then the future picture looks better. Hopefully these types of announcements are a sign that short-term financing from placings is a thing of the past, and that the business is becoming cash flow positive. As a holder that is what I really want to see as it will have a significant impact on the share price Jay |
Posted at 16/11/2009 09:10 by jaylett IndunaI have an investment management background and I'm very comfortable with my level of exposure to CUS. The stock currently makes up about 5% of my total portfolio size, which is diversified between small and large caps across a number of sectors I like at present. I have considered adding a couple % more in CUS, pending the upcoming set of results. As you say, concentrating your portfolio in a couple of these volatile small-cap names is a very, very dangerous thing to do. If the last 18 months haven't taught private investors the lesson of diversification then nothing will. Thanks for your concern around my investment strategy, but I'm happy with my current 'predicament'. Jay |
Posted at 13/11/2009 14:01 by induna123 Well quite frankly if you're already down a grand then you've invested way more than I'm prepared to put into small caps like these. I'm only down a £100 on the current spread which I can live with. Stocks like these can be dangerous if you put too much of your capital in them. I used to do that but now I'm more conservative. I've learned my lesson as I too used to get stung quite often. And try not hold too many stocks at the same time. Conserve your cash. I note Jay said he already holds a fair amount of these and even thought about buying more. That would be foolish imo. Not becuase CUS is a bad company but because you don't want to over-expose yourself in one stock as you'll end up trapping all your capital if the share price goes down. No point looking for sympathy or looking to blame others for your predicament, only you can rectify the situation. |
Posted at 13/11/2009 08:22 by jaylett 'Nothing to do with CUS'.The share price of CUS has everything to do with CUS. It reflects the market's sentiment towards it, and while the overall market mood will have a knock-on effect, it is a minor one against the confidence the market holds in CUS. I'm a holder of a decent sized position here, and while the recent news was good, it wasn't the company changer it's been made out to be IMO. We still need hard sales of products, and cash coming in the door in the short-term. Until that time, the spectre of more placings to raise short-term cash will keep the share price depressed. That's why CUS is not holding the gains it made, not because of general market malaise. We are still waiting for the Annuals and Moorfields results, which were referenced in a previous RNS as being due 'in early November'. I sent CUS an email asking for a date, they have not replied. The contents of that RNS when it comes will be of huge importance to CUS and will dictate whether I sell and walk away or increase my holding. Jay |
Posted at 06/11/2009 13:21 by alcatraz10 Presbyopia Approval (Customvis)TIDMCUS RNS Number : 1047C CustomVis plc 06 November 2009 Presbyopia Approval CustomVis (AIM: CUS), the leading developer, manufacturer and distributor of solid state laser systems for the refractive surgical industry is pleased to announce it has been granted approval for its presbyopia treatment by the Therapeutic Goods Administration ("TGA"), Australia's regulatory agency for medical drugs and devices. The approval is a major achievement for the Group, becoming one of the first refractive laser developers in the world to be granted regulatory approval for the treatment of presbyopia. As well as Australian approval, the treatment has been granted European CE approval, allowing the procedure to be carried out within the European Union. The Directors believe this is the first presbyopia treatment of this method of laser surgery to receive CE approval. Presbyopia is an age-associated progressive loss of the focusing power of the eye's lens, making it difficult to see objects close-up. Most people over the age of 40 will suffer from it to some degree and current treatment options are limited, generally meaning the use of reading glasses, bifocal glasses or the invasive insertion of intraocular lenses, none of which offer a true solution. CustomVis, over the past few years, has pioneered a technique which will restore close-up vision while the patient retains good long distance sight. The Group's installed base of Pulzar Z1 lasers will be capable of conducting the PresBvis(TM) presbyopia treatment through this regulatory approval. The Group expects to conduct simple software upgrades over the next two months, thereby allowing surgeons operating the Pulzar Z1 lasers to begin offering this treatment to their patients shortly. PresBvis(TM) users will be charged on a per-patient basis, bringing a new cash flow stream into the business, with fees paid in advance to CustomVis for each treatment performed. Dr. Paul van Saarloos, Chief Executive of CustomVis, commented, "Being one of the first laser developers in the world to offer this highly specialised treatment for a very common problem will give us a big competitive advantage. As well as being a new and additional source of revenue for the Group we anticipate it will lead to expanded sales of the Pulzar Z1." |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
